# Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge

> **NCT06069063** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Allergy & Asthma Medical Group & Research Center** · enrollment: 12 (estimated)

## Conditions studied

- Allergy to Cats

## Interventions

- **DRUG:** Zafirlukast

## Key facts

- **NCT ID:** NCT06069063
- **Lead sponsor:** Allergy & Asthma Medical Group & Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06069063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06069063, "Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06069063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*